HRP20110539T1 - PIRIDINO[3,4-b]PIRAZINONI - Google Patents

PIRIDINO[3,4-b]PIRAZINONI Download PDF

Info

Publication number
HRP20110539T1
HRP20110539T1 HR20110539T HRP20110539T HRP20110539T1 HR P20110539 T1 HRP20110539 T1 HR P20110539T1 HR 20110539 T HR20110539 T HR 20110539T HR P20110539 T HRP20110539 T HR P20110539T HR P20110539 T1 HRP20110539 T1 HR P20110539T1
Authority
HR
Croatia
Prior art keywords
group
substituents
propoxyethyl
alkyl
pyrido
Prior art date
Application number
HR20110539T
Other languages
English (en)
Croatian (hr)
Inventor
O. Hughes Robert
Simon Bell Andrew
Graham Brown David
Rhys Owen Dafydd
John Palmer Michael
Phillips Christopher
Louis Brown David
Marlene Fobian Yvette
Nicholas Freskos John
Edward Heasley Steven
Jon Jacobsen Eric
Michael Maddux Todd
Virgil Mischke Brent
Major Molyneaux John
Blair Moon Joseph
Joseph Jr. Rogier Donald
Brent Tollefson Michael
Keith Walker John
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HRP20110539T1 publication Critical patent/HRP20110539T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epoxy Compounds (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20110539T 2006-04-21 2007-04-10 PIRIDINO[3,4-b]PIRAZINONI HRP20110539T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79397106P 2006-04-21 2006-04-21
PCT/IB2007/001001 WO2007122466A1 (en) 2006-04-21 2007-04-10 Pyridine[3,4-b]pyrazinones

Publications (1)

Publication Number Publication Date
HRP20110539T1 true HRP20110539T1 (hr) 2011-08-31

Family

ID=38431249

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110539T HRP20110539T1 (hr) 2006-04-21 2007-04-10 PIRIDINO[3,4-b]PIRAZINONI

Country Status (41)

Country Link
US (1) US7902195B2 (enExample)
EP (1) EP2013208B1 (enExample)
JP (1) JP4436892B2 (enExample)
KR (1) KR101061328B1 (enExample)
CN (1) CN101454320B (enExample)
AP (1) AP2408A (enExample)
AR (1) AR060525A1 (enExample)
AT (1) ATE513831T1 (enExample)
AU (1) AU2007242555B2 (enExample)
BR (1) BRPI0710658A2 (enExample)
CA (1) CA2649775C (enExample)
CR (1) CR10327A (enExample)
CU (1) CU23777B7 (enExample)
CY (1) CY1111739T1 (enExample)
DK (1) DK2013208T3 (enExample)
DO (1) DOP2007000080A (enExample)
EA (1) EA014919B1 (enExample)
EC (1) ECSP088803A (enExample)
ES (1) ES2366239T3 (enExample)
GT (1) GT200700035A (enExample)
HR (1) HRP20110539T1 (enExample)
IL (1) IL194591A (enExample)
MA (1) MA30352B1 (enExample)
ME (1) MEP23808A (enExample)
MX (1) MX2008012456A (enExample)
MY (1) MY148583A (enExample)
NL (1) NL2000583C2 (enExample)
NO (1) NO20084129L (enExample)
NZ (1) NZ571540A (enExample)
PA (1) PA8724201A1 (enExample)
PE (1) PE20080192A1 (enExample)
PL (1) PL2013208T3 (enExample)
RS (2) RS20080484A (enExample)
SI (1) SI2013208T1 (enExample)
SV (1) SV2008003074A (enExample)
TN (1) TNSN08408A1 (enExample)
TW (1) TWI337609B (enExample)
UA (1) UA92637C2 (enExample)
UY (1) UY30291A1 (enExample)
WO (1) WO2007122466A1 (enExample)
ZA (1) ZA200808283B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2013208B1 (en) 2006-04-21 2011-06-22 Pfizer Products Inc. Pyridin[3,4-b]pyrazinones
AU2007333115B2 (en) 2006-12-12 2013-01-10 Gilead Sciences, Inc. Composition for treating a pulmonary hypertension
KR101589628B1 (ko) 2008-03-05 2016-01-28 메르크 파텐트 게엠베하 인슐린 분비 자극제들로서의 피리도피라지논 유도체들, 이들을 얻기 위한 방법들 및 당뇨병 치료를 위한 이들의 용도
EP2351748A4 (en) * 2008-10-09 2012-03-21 Kyorin Seiyaku Kk ISOCHINOLINE DERIVATIVES AND THESE PDE INHIBITORS CONTAINING ACTIVE SUBSTANCE
CA2778615C (en) * 2009-10-26 2019-04-23 Signal Pharmaceuticals, Llc Methods of synthesis and purification of heteroaryl compounds
HUE033346T2 (en) 2010-10-15 2017-11-28 Gilead Sciences Inc Compositions and methods for treating pulmonary hypertension
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
ES2605565T3 (es) 2011-08-31 2017-03-15 Pfizer Inc Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina
ES2585262T3 (es) 2012-05-04 2016-10-04 Pfizer Inc Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
WO2014045162A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-ANIME COMPOUNDS
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
EP2931731A1 (en) 2012-12-11 2015-10-21 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014125394A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
KR20150119370A (ko) 2013-02-19 2015-10-23 화이자 인코포레이티드 Cns 장애 및 다른 장애의 치료를 위한 pde4 동종효소의 억제제로서의 아자벤즈이미다졸 화합물
CA2925743C (en) 2013-10-04 2018-03-06 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
EP3126361B1 (en) 2014-04-01 2019-11-06 Pfizer Inc Chromene and 1,1a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
AP2016009493A0 (en) 2014-04-10 2016-10-31 Pfizer 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
WO2016020786A1 (en) 2014-08-06 2016-02-11 Pfizer Inc. Imidazopyridazine compounds
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
HUE051898T2 (hu) 2015-06-17 2021-03-29 Pfizer Triciklusos vegyületek és alkalmazásuk foszfodiészteráz inhibitorokként
EP3353174A1 (en) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors
AU2016325665A1 (en) 2015-09-24 2018-03-08 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
WO2017051303A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
PT3419979T (pt) 2016-02-23 2020-03-26 Pfizer Compostos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
MX386258B (es) 2016-07-01 2025-03-18 Pfizer Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas
KR20200013783A (ko) 2017-06-22 2020-02-07 화이자 인코포레이티드 디히드로-피롤로-피리딘 유도체
CA3067591A1 (en) * 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
HUE061533T2 (hu) 2018-03-23 2023-07-28 Pfizer Piperazin azaspiro származékok
EP4297868A4 (en) 2021-02-23 2025-01-08 Hoth Therapeutics, Inc. USE OF APREPITANT TO TREAT ALZHEIMER'S
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2025145091A1 (en) 2023-12-29 2025-07-03 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases
WO2025160132A1 (en) * 2024-01-23 2025-07-31 Maplight Therapeutics, Inc. Gpr6 inverse agonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1361652A (fr) 1963-06-21 1964-05-22 Ciba Geigy Procédé de préparation de diazines, entre autres de la 2-méthyl-6-hydroxy-7-morpholino-ptéridine
ATE194985T1 (de) * 1990-11-06 2000-08-15 Yamanouchi Pharma Co Ltd Kondensiertes pyrazinderivat
TW274550B (enExample) * 1992-09-26 1996-04-21 Hoechst Ag
JP2000154139A (ja) 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd 縮環ピラジン誘導体
US6369056B1 (en) * 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6465465B1 (en) * 2000-03-14 2002-10-15 Arzneimittelwerk Dresden Gmbh Process for the treatment of erectile dysfunction and product therefor
EP1364950A4 (en) * 2001-02-26 2005-03-09 Tanabe Seiyaku Co Pyridopyrimidine and naphthyridine derivatives
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US7067658B2 (en) * 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
US20070053831A1 (en) * 2003-05-20 2007-03-08 Barrio Jorge R Methods for binding agents to b-amyloid plaques
WO2005013894A2 (en) * 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
EP1833803A4 (en) * 2005-01-03 2009-08-05 Myriad Genetics Inc PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCTORS OF APOPTOSIS AND THEIR USE
WO2006126082A2 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
EP1940805A4 (en) * 2005-08-26 2009-11-11 Methylgene Inc BENZODIAZEPIN AND BENZOPIPERAZINANALOGA AS INHIBITORS OF HISTONDEACETYLASE
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2013208B1 (en) 2006-04-21 2011-06-22 Pfizer Products Inc. Pyridin[3,4-b]pyrazinones

Also Published As

Publication number Publication date
GT200700035A (es) 2008-02-05
NL2000583C2 (nl) 2007-12-14
UA92637C2 (en) 2010-11-25
US20070249615A1 (en) 2007-10-25
AP2408A (en) 2012-05-30
CN101454320B (zh) 2012-12-19
TWI337609B (en) 2011-02-21
US7902195B2 (en) 2011-03-08
SI2013208T1 (sl) 2011-09-30
EP2013208A1 (en) 2009-01-14
TNSN08408A1 (fr) 2010-04-14
TW200808794A (en) 2008-02-16
IL194591A (en) 2012-07-31
EA200801998A1 (ru) 2009-04-28
CA2649775A1 (en) 2007-11-01
ZA200808283B (en) 2009-11-25
AR060525A1 (es) 2008-06-25
JP2009534368A (ja) 2009-09-24
KR20080110930A (ko) 2008-12-19
PA8724201A1 (es) 2009-08-26
PL2013208T3 (pl) 2011-10-31
PE20080192A1 (es) 2008-03-01
AU2007242555B2 (en) 2010-12-16
KR101061328B1 (ko) 2011-08-31
MEP23808A (en) 2010-06-10
NL2000583A1 (nl) 2007-10-23
CU23777B7 (es) 2012-02-15
BRPI0710658A2 (pt) 2011-08-16
MX2008012456A (es) 2008-10-10
CY1111739T1 (el) 2015-10-07
DOP2007000080A (es) 2007-11-15
CA2649775C (en) 2011-05-31
MA30352B1 (fr) 2009-04-01
CN101454320A (zh) 2009-06-10
NZ571540A (en) 2010-10-29
EP2013208B1 (en) 2011-06-22
DK2013208T3 (da) 2011-08-15
HK1133875A1 (en) 2010-04-09
NO20084129L (no) 2008-10-29
ATE513831T1 (de) 2011-07-15
MY148583A (en) 2013-04-30
JP4436892B2 (ja) 2010-03-24
EA014919B1 (ru) 2011-04-29
SV2008003074A (es) 2010-01-12
CR10327A (es) 2008-10-21
RS20080484A (sr) 2009-07-15
UY30291A1 (es) 2007-11-30
AU2007242555A1 (en) 2007-11-01
ES2366239T3 (es) 2011-10-18
WO2007122466A1 (en) 2007-11-01
CU20080194A7 (es) 2011-03-21
ECSP088803A (es) 2008-11-27
AP2008004640A0 (en) 2008-10-31
RS51885B (sr) 2012-02-29

Similar Documents

Publication Publication Date Title
HRP20110539T1 (hr) PIRIDINO[3,4-b]PIRAZINONI
JP2009534368A5 (enExample)
ES2697174T3 (es) Compuestos para tratar atrofia muscular espinal
US9428506B2 (en) Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
RU2728787C2 (ru) Органические соединения
HRP20200624T1 (hr) Derivati 2-(2,4,5-supstituiranog-anilino)pirimidina kao modulatori egfr korisni za liječenje raka
KR101720824B1 (ko) 카테콜 ｏ-메틸 트랜스퍼라제의 억제제 및 정신병적 장애의 치료에서의 그의 용도
JP2009524676A5 (enExample)
JP2019510039A (ja) 新規組成物および方法
CN101448829A (zh) 4-氨基-吡啶并[3,2-e]吡嗪类，其作为磷酸二酯酶10的抑制剂的用途以及制备它们的方法
WO2015154030A1 (en) Organic compounds
CN109641898A (zh) 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物
WO2017165755A1 (en) Organic compounds
HRP20160647T1 (hr) Novi heterociklički derivati i njihova uporaba u liječenju neuroloških poremećaja
AU2005215257A1 (en) Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
ATE370138T1 (de) Neue imidazopyridine und ihre verwendung
AR053011A1 (es) Compuestos de heteroarilo como inhibidores del receptor p2y1, composiciones farmaceuticas que los contienen y su uso en la manufactura de un medicamento para el tratamiento de un trastorno tromboembolico
RU2016110483A (ru) Производные пирролопиридина или пиразолопиридина
JP6285610B2 (ja) アゼチジニルオキシフェニルピロリジン化合物
RU2019125177A (ru) Новые производные амино-имидазопиридина в качестве ингибиторов янус-киназы и их фармацевтическое применение
NO20080393L (no) Halogenerte pyrazolo [1,5-A] pyrimidiner, fremgangsmater, anvendelse som GABA-A reseptorligander, sammensetninger og intermediater
JP2017523201A5 (enExample)
BRPI0610028A2 (pt) combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos
KR20250114139A (ko) 치환된 테트라하이드로피롤로-피리디논 화합물 및 의학적 병태 치료에서의 이의 용도
AR037611A1 (es) Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden